| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 01/25 | 11/27 | | |
| Recruiting | N/A | 3000 | Europe | | Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l. | Solid Tumours in Advanced Stages | 10/26 | 10/26 | | |
